Kinase News and Research

RSS

Study finds how long-term memory encoded engram neurons are formed

While long-term memory is known to be encoded in specific neural cells, engram neurons, it has been unclear how these engram neurons are formed during training.

28 Dec 2018

Targeting thymidylate biosynthesis in kinetoplastid and apicomplexan protozoans

Kinetoplastid and apicomplexan parasites include protozoans which are responsible for human diseases, and cause a serious impact on human health and the socioeconomic growth of developing countries. Chemotherapy is the main option to control these pathogenic organisms.

27 Dec 2018

CWRU researcher receives nearly $1 million to study drug resistance mechanisms in prostate cancer

Sanjay Gupta, PhD, of Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center will receive $962,000 over three years to investigate drug resistance mechanisms in prostate cancer.

24 Dec 2018

Study shows how a novel regulatory mechanism serves as key biomarker for diabetes

A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential therapeutic target for its prevention.

20 Dec 2018

Novel insight on inflammatory regulation could pave way for effective pain therapies

A novel way in which the inflammatory response to pain is regulated has been described in the open-access journal eLife.

19 Dec 2018

Green leafy vegetables may reduce risk of developing liver steatosis

A larger portion of green leafy vegetables in the diet may reduce the risk of developing liver steatosis, or fatty liver. In a study published in PNAS researchers from Karolinska Institutet in Sweden show how a larger intake of inorganic nitrate, which occurs naturally in many types of vegetable, reduces accumulation of fat in the liver.

17 Dec 2018

Statins associated with low risk of side effects

The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients.

10 Dec 2018

Researchers report novel findings on plant hormone

Jasmonic acid is not just the aromatic odor of the plant Jasminum grandiflorum used in cosmetics and perfume industries. Plants wounded by e.g. chewing herbivores produce jasmonic acid as a defense signal, as a phytohormone to mount their defense responses - this includes for example the formation of toxic substances.

10 Dec 2018

Failure of critical cellular energy sensor responsible for CKD progression, study finds

Chronic kidney disease, an affliction characterized by progressive loss of kidney function, affects millions of people worldwide and is associated with multi-organ damage, cardiovascular disease, and muscle wasting.

7 Dec 2018

Newly developed molecules may provide more reliable relief for people with autoimmune diseases

Living with an autoimmune disease can feel like an insider is attacking your body. An estimated 24 million people in the United States are affected by autoimmune diseases, a group of diseases in which a person's immune system attacks part of the person's own body.

7 Dec 2018

New drug combination could kill melanoma cells more effectively, study shows

A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient.

3 Dec 2018

Triple combination cancer immunotherapy improves survival in mouse model of melanoma

Adoptive cell transfer is a promising cancer immunotherapy that involves isolating T cells from cancer patients that are capable of targeting their tumor, selecting the more active T cells and expanding those in the lab, and then transfusing them back into patients.

30 Nov 2018

FDA grants accelerated approval to oncology drug for treatment of key genetic driver of cancer

The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

27 Nov 2018

UC San Francisco scientists identify 'Achilles heel' of drug-resistant cancers

UC San Francisco scientists have figured out why some lung cancers become drug-resistant after initially responding to targeted therapies.

27 Nov 2018

Scientists identify novel target for neuron regeneration, functional recovery in spinal cord injury

Restoring the ability to walk following spinal cord injury requires neurons in the brain to reestablish communication pathways with neurons in the spinal cord.

20 Nov 2018

Towards finding a druggable cancer target

It's known that cancer involves unchecked cell growth and that a biological pathway that regulates organ size, known at the Hippo pathway, is also involved in cancer.

19 Nov 2018

Study shows new emerging role of osteopontin in HCV-related hepatocellular carcinoma

Hepatitis C virus (HCV) infection is the major cause of hepatocellular carcinoma (HCC) and was estimated to be responsible for 745,000 deaths in 2012.

13 Nov 2018

CDK2 protein plays key role in heart damage caused by doxorubicin, finds study

A new study by Washington State University researchers suggests that a protein called CDK2 plays a critical role in heart damage caused by doxorubicin, a commonly used chemotherapy drug.

8 Nov 2018

New nuclear medicine tracer could improve diagnosis, treatment of non-small cell lung cancer

Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer.

7 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018